Lack of detrimental effects of nitric oxide inhibition in bile duct-ligated rats with hepatic encephalopathy

European Journal of Clinical Investigation

Volumn 34, Issue 2, 2004, Pages 122-128

  Chan, C Y ^a,c   Huang, S W ^c   Wang, T F ^a,b   Lu, R H ^a   Lee, F Y ^a,c   Chang, F Y ^a,c   Chu, C J ^a,c   Chen, Y C ^a   Chan, C C ^a,c   Huang, H C ^a,c   Lee, S D ^a,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Armed Forces Sung Shan Hospital   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Hepatic encephalopathy; Nitric oxide; Tumour necrosis factor ; Vasodilatation

Indexed keywords

N(G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE; NITRITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; BILIARY CIRRHOSIS; BLOOD LEVEL; CONTROLLED STUDY; HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD PRESSURE; HEART RATE; HEPATIC ENCEPHALOPATHY; MALE; MOTOR ACTIVITY; NG-NITROARGININE METHYL ESTER; NITRATES; NITRIC OXIDE; NITRITES; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA; VASODILATION;

EID: 1342331363     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01295.x     Document Type: Article

References (63)

1. Gammal SH, Hones EA. Hepatic encephalopathy. Med Clin North Am 1989;73:793-813.
2. Sherlock S. Fulminant hepatic failure. Adv Intern Med 1993;38:245-67.
3. Mousseau DD, Butterworth RF. Current theories on the pathogenesis of hepatic encephalopathy. Soc Exp Biol Med 1994;206:329-44.
4. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994;20:1359-63.
5. Palmer PMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from 1-arginine. Nature 1988;333:664-7.
6. Pizcueta MP, Piqué JM, Bosch J, Whittle BJR, Moncada S. Effects of inhibiting nitric oxide synthase on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992;105:184-90.
7. ω- nitro-L-arginine administration corrects peripheral vasodilatation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993;17:84-90.
8. Lockwood AH, Yap EWH, Wong W. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cerebr Blood Flow Metab 1991;11:337-41.
9. Janigro D, West GA, Nguyen TS, Winn HR. Regulation of blood-brain barrier endothelial cells by nitric oxide. Circ Res 1994;75:528-38.
10. 2 formation parallels blood-brain barrier disruption in an experimental rat model of bacterial meningitis. Brain Res Bull 1998;46:541-6.
11. Larsen FS, Ejlersen E, Hansen BA, Knudsen GM, Tygstrup N, Secher NH. Functional loss of cerebral blood flow autoregulation in patients with fulminant hepatic failure. J Hepatol 1995;46:212-7.
12. Larsen FS, Knudsen GM, Paulson OB, Vilstrup H. Cerebral blood flow autoregulation is absent in rats with fulminant hepatic failure. J Hepatol 1994;21:491-5.
13. Aggarwal S, Kramer D, Yonas H, Obrist W, Kang Y, Martin M et al. Cerebral hemodynamic and changes in fulminant hepatic failure: a retrospective study. Hepatology 1994;19:80-7.
14. Rao VL, Audet RM, Butterworth RF. Increased neuronal nitric oxide synthase expression in brain following portacaval anastomosis. Brain Res 1997;765:169-72.
15. Rao VL, Butterworth RF. Neuronal nitric oxide synthase and hepatic encephalopathy. Metab Brain Dis 1998;13:175-89.
16. Schliess F, Haussinger D. Hepatic encephalopathy and nitric oxide. J Hepatol 2001;34:610-2.
17. Rao VL. Nitric oxide in hepatic encephalopathy and hyperammonemia. Neurochem Int 2002;41:161-70.
18. Diez-Fernandez C, Sanz N, Bosca L, Hortelano S, Cascales M. Involvement of nitric oxide synthesis in hepatic perturbations induced in rats by a necrogenic dose of thioacetamide. Br J Pharmacol 1997;121:820-6.
19. Kosenko E, Kaminsky Y, Grau E, Misana MD, Grisolia S, Felipo V. Nitroarginine, an inhibitor of nitric oxide synthase, attenuates ammonia toxicity and ammonia-induced alterations in brain metabolism. Neurochem Res 1995;20:451-6.
20. Chu CJ, Wang SS, Lee FY, Change FY, Lin MC, Hou CC et al. Detrimental effects of nitric oxide inhibition on hepatic encephalopathy in rats with thioacetamide-induced fulminant hepatic failure. Eur J Clin Invest 2001;31:156-63.
21. Klin MJ, Waluga M, Madej A, Plewka A, Herman ZS. Hypothalamic, striatal and plasma leucine enkephalin level in two rat models of portal hypertension. Pol J Pharmacol 1993;45:281-90.
22. Minuk GY, Sarjeant EJ. The effect of (a) neomycin and lactulose treatment on systemic and portal serum GABA levels in rats and (b) pH changes on [3H] GABA binding to isolated rat hepatocytes. Clin Invest Med 1988;11:373-6.
23. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct ligation obstruction: a new experimental model of cirrhosis in the rat. Br J Exp Pathol 1984;65:305-11.
24. Lebrec D, Blanchet L. Effect of two models of portal hypertension on splanchnic organ blood flow in the rat. Clin Sci 1985;68:23-8.
25. Fernandez M, Pizcueta P, Garcia-Pagan JC, Feu F, Cirera I, Bosch J et al. Effects of ritanserin, a selective and specific S2-serotoninergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. Hepatology 1993;18:389-93.
26. Castaneda B, Debernardi-Venon W, Bandi JC, Andreu V, Perez del Pulgar S, Moitinho E et al. The role of portal pressure in the severity of bleeding in portal hypertensive rats. Hepatology 2000;31:581-6.
27. A-benzodiazepine receptor on hepatic encephalopathy in the rat: comparison with uremic encephalopathy. Hepatology 1991;14:963-8.
28. Bengtsson F, Gage FH, Jeppsson B, Nobin A, Rosengren E. Brain monoamine metabolism and behavior in portocaval shunted rats. Exp Neruol 1985;90:21-35.
29. ω-nitro-L-arginine ameliorates portal-systemic shunting in poral-hypertensive rats. Gastroenterology 1993;105:1464-70.
30. Lee FY, Wang SS, Tsai YT, Lin HJ, Lin HC, Chu CJ et al. Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats. J Hepatol 1997;26:687-93.
31. Blei AT, Larsen FS. Pathophysiology of cerebral edema in fulminant hepatic failure. J Hepatol 1999;31:771-6.
32. Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocytes swelling and low-grade cerebral edema. J Hepatol 2000;32:1035-8.
33. Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis 2002;17:221-7.
34. Vaquero J, Chung C, Cahill ME, Blei AT. Pathogenesis of hepatic encephalopathy in acute liver failure. Semin Liver Dis 2003;23:259-69.
35. Rahman TM, Hodgson HJ. Animal models of acute hepatic failure. Int J Exp Pathol 2000;81:145-57.
36. Newsome PN, Plevris JN, Nelson LJ, Hayes PC. Animal models of fulminant hepatic failure: a critical evaluation. Liver Transpl 2000;6:21-31.
37. Rigotti P, Jonung T, James JH, Edwards LL, Peters JC, Fischer JE. Infusion of branched-chain amino acids and ammonium salts in rats with portacaval shunts. Arch Surg 1985;120:1290-5.
38. Hawkins PA, DeJoseph MR, Vina JR, Hawkins RA. Comparison of the metabolic disturbances caused by end-to-side and side-to-side portacaval shunts. J Appl Physiol 1996;80:885-91.
39. Koyama K, Muto I, Yamauchi H, Takagi Y, Anezaki T. Biochemical study of fibrosis in the rat liver in biliary obstruction. Tohoku J Exp Med 1975;116:161-72.
40. Chu CJ, Lee FY, Wang SS, Change FY, Lin HC, Wu SL et al. Establishment of an animal model of hepatic encephalopathy. J Chin Med Assoc 2000;63:263-9.
41. Mayoral P, Criado M, Hidalgo F, Flores O, Arevalo MA, Eleno N et al. Effects of chronic nitric oxide activation or inhibition on early hepatic fibrosis in rats with bile duct ligation. Clin Sci 1999;96:297-305.
42. Clemens MG. Nitric oxide in liver injury. Hepatology 1999;30:1-5.
43. Wolkow PP. Involvement and dual effects of nitric oxide in septic shock. Inflamm Res 1998;47:152-66.
44. Statman R, Cheng W, Cunningham JN, Henderson JL, Damiani P, Siconolfi A et al. Nitric oxide inhibition in the treatment of the sepsis syndrome is detrimental to tissue oxygenation. J Surg Res 1994;57:93-8.
45. Malyshev I-Yu, Malugin AV, Manukhina EB, Larionov NP, Malenyuk EB, Malysheva EV et al. Is HSP70 involved in nitric oxide-induced protection of the heart? Physiol Res 1996;45:267-72.
46. Kim YM, de Vera ME, Watkins SC, Billiar TR. Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor-alpha-induced apoptosis by inducing heat shock protein 70 expression. J Biol Chem 1997;272:1402-11.
47. Nisoli E, Regianini L, Bulbarelli A, Briscini L, Breacale R, Carruba MO. Protective effects of noradrenaline against tumor necrosis factor-alpha-induced apoptosis in cultured rat brown adipocytes: role of nitric oxide-induced heat shock protein 70 expression. Int J Obes Relat Metab Disord 2001;25:1421-30.
48. Dalmau M, Joaquin M, Nakamura T, Bartrons R, Gil J. Nitric oxide inhibits DNA synthesis and induces activation of poly (ADP-ribose) polymerase in cultured rat hepatocytes. Exp Cell Res 1996;228:14-8.
49. Pieper AA, Verma A, Zhang J, Snyder SH. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 1999;20:171-81.
50. Brune B, Zhou J, von Knethen A. Nitric oxide, oxidative stress, and apoptosis. Kidney Int 2003;84:S22-4.
51. Hortelano S, Dallaporta B, Zamzami N, Hirsch T, Susin SA, Marzo I et al. Nitric oxide induces apoptosis via triggering mitochondrial permeability transition. FEBS Lett 1997;410:373-7.
52. Szabo C, Ohshima H. DNA damage induced by peroxynitrite: subsequent biological effects. Nitric Oxide 1997;1:373-85.
53. Szabo C. DNA strand breakage and activation of poly-ADP ribosyltransferase: a cytotoxic pathway triggered by peroxynitrite. Free Radic Biol Med 1996;21:855-69.
54. Laubach VE, Foley PL, Shockey KS, Tribble CG, Kron IL. Protective roles of nitric oxide and testosterone in endotoxemia: evidence from NOS-2-deficient mice. Am J Physiol 1998;275:H2211-8.
55. Larsen FS, Gottstein J, Blei AT. Cerebral hyperemia and nitric oxide synthase in rats with ammonia-induced brain edema. J Hepatol 2001;34:548-54.
56. Pelligrino DA, Gay RL 3rd, Baughman VL, Wang Q. NO synthase inhibition modulates NMDA-induced changes in cerebral blood flow and EEG activity. Am J Physiol 1996;271 (3 Part 2):H990-5.
57. Schliess F, Gorg B, Fischer R, Desjardins P, Bidmon HJ, Herrmann A et al. Ammonia induces MK-801-sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes. FASEB J 2002;16:739-41.
58. Gorg B, Foster N, Reinehr R, Bidmon HJ, Hongen A, Haussinger D et al. Benzodiazepine-induced protein tyrosine nitration in rat astrocytes. Hepatology 2003;37:334-42.
59. Norenberg MD. Oxidative and nitrosative stress in ammonia neurotoxicity. Hepatology 2003: 245-8.
60. Chung C, Gottstein J, Blei AT. Indomethacin prevents the development of experimental ammonia-induced brain edema in rats after portacaval anastomosis. Hepatology 2001;34:249-54.
61. Koehler RC, Traystman RJ. Cerebrovascular effects of carbon monoxide. Antioxid Redox Signal 2002;4:279-90.
62. Johnson RA, Kozma F, Colombari E. Carbon monoxide: from toxin to endogenous modulator of cardiovascular functions. Braz J Med Biol Res 1999;32:1-14.
63. Horvath B, Hrabak A, Kaldi K, Sandor P, Benyo Z. Contribution of the heme oxygenase pathway to the maintenance of the hypothalamic blood flow during diminished nitric oxide synthesis. J Cereb Blood Flow Metab 2003;23:653-7.